GILEAD SCIENCES NASDAQ: GILD
Background of Gilead Sciences
- Gilead Sciences Inc is an American biopharmaceutical company that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza.
- Gilead Sciences Inc is headquartered in Foster City, California.
- Gilead Sciences Inc is a member of the NASDAQ Biotechnology Index and the S&P 500 and oversees a high-value product portfolio which include products for the treatment of human immunodeficiency virus (HIV) infection, the treatment of coronavirus disease 2019, treatment of liver diseases, as well as products for haematology, oncology, and cell therapy patients.
- Gilead Sciences Inc has a rich history that dates to 1987, when it was founded by Michael L. Riordan, a medical doctor, and three scientific advisers, under the name Oligogen.
- Gilead Sciences Inc’s first therapeutic focus was on antiviral medicines, and soon changed its name to Gilead Sciences after the alleged healing properties of the ancient Balm of Gilead because of the research’s expected healing potential.
- Gilead Sciences Inc debuted on the NASDAQ in January 1992 with its initial public offering raising $86.25 million in proceeds.
- In 1999, Gilead Sciences Inc acquired NeXstar Pharmaceuticals of Boulder, Colorado, who sold an injectable fungal treatment, and an oncology drug taken by HIV patients, and which had already built its own sales force in Europe.
- In 2002, Gilead Sciences Inc changed corporate strategy and focus exclusively on antivirals, and sold its cancer assets to OSI Pharmaceuticals.
- In 2002, Gilead Sciences Inc acquired Triangle and announced its first full year of profitability.
- Gilead Sciences Inc gradually completed an evolution from a biotech start-up into a pharmaceutical company although it kept a strong reliance on subcontracting manufacturing organizations.
- In 2004, during the Avian Flu pandemic scare, Gilead Sciences Inc’s revenue from Tamiflu almost quadrupled to $44.6m as more than 60 national governments stocked up on the antiviral drug.
- In 2006, Gilead Sciences Inc acquired two more companies which launched it further into the cardiovascular and respiratory therapeutic arenas.
- Gilead Sciences Inc purchased Raylo Chemicals, Inc., a custom manufacturer of active pharmaceutical ingredients and advanced intermediates for the pharmaceutical and biopharmaceutical industries, in 2006 and later in the year also Myogen, Inc.
- Gilead Sciences Inc expanded into respiratory therapeutics in 2007 by entering into a licensing agreement with Parion for an epithelial sodium channel inhibitor for the treatment of pulmonary diseases.
- In 2009, the company acquired CV Therapeutics, Inc., obtaining cardiovascular drugs used to treat chest pain in coronary artery disease.
- Also, in 2009 Gilead Sciences Inc was named one of the Fastest Growing Companies by Fortune and one America’s Top Companies to work for by Forbes.
- In 2010, Gilead Sciences Inc acquired first CGI Pharmaceuticals, expanding research expertise into kinase biology and chemistry and then Arresto Biosciences, Inc., obtaining developmental-stage research for treating fibrotic diseases and cancer.
- In 2011, Gilead Sciences Inc acquired Calistoga Pharmaceuticals which boosted its oncology and inflammation solutions and its most important and expensive acquisition, Pharmasset Inc. to become the leader in treatment of the hepatitis C virus.
- In 2013, Gilead Sciences Inc acquired YM Biosciences, Inc. and in 2015, it bought Phenex Pharmaceuticals, EpiTherapeutics and an equity stake in Galapagos NV.
- In 2016, Gilead Sciences Inc acquired Nimbus Apollo, Inc. and was also named the most generous company on the 2016 Fortune list since its charitable donations to HIV/AIDS and liver disease organizations totalled over 440 million in 2015.
- In 2017, Gilead Sciences Inc acquired Kite Pharma and Cell Design Labs.
- In 2025, Gilead Sciences Inc acquired Forty-Seven Inc. and in June 2025, AstraZeneca Plc had made a preliminary approach to Gilead for a potential merger.
- In September 2025, Gilead announced the acquisition of Immunomedics and German biotech, MYR GmbH.
- Today, Gilead Sciences Inc is truly one of the most valuable healthcare companies in the world with a market capitalization of US$ 86.42billion recorded in July 2025.
- In 2025 the total staff compliment for Gilead Sciences Inc was more than 13 600.
- In July 2025 Gilead Sciences Inc’s executive leadership team consisted of: Daniel O’Day – Chairman of the Board, Chief Executive Officer; Andrew D. Dickinson – Chief Financial Officer; Brett Alan Pletcher – Executive Vice President – Corporate Affairs, General Counsel, Company Secretary; Flavius Martin – Executive Vice President – Research; and Johanna Mercier – Chief Commercial Officer.
Gilead Sciences Shares Growth Driver
- Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops, and commercializes medicines in areas of unmet medical need.
- Gilead Sciences Inc’s portfolio of products and pipeline of investigational drugs includes treatments HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
- Gilead Sciences Inc benefited from the expansion of Medicaid in the ACA although its HIV drugs could face funding pressure under reform proposals.
- Gilead Sciences Inc has $32 billion in cash, but $27.4 billion is outside the U.S. and unavailable for acquisitions unless Gilead pays U.S. tax on it, so the company would benefit from proposals to let companies repatriate offshore capital with minimal further taxation.
- As such, the company’s innovative and competitive portfolio has allowed it to defy the market trends surrounding the coronavirus pandemic, with performance and shares still attractive after a tumultuous 2025.
Gilead Sciences Investor Tip
- Gilead Sciences Inc trades its shares on the NASDAQ Stock Market (NASDAQ) under the stock symbol GILD. Gilead Sciences Inc forms part of the NASDAQ-100, S&P 100, and S&P 500 Components.
- An analysis on Gilead Sciences Inc’s market performance and income statement indicates Revenue (ttm) of 25.56 billion, Revenue Per Share (ttm) 20.36, Quarterly Revenue Growth (yoy) 15.80%, Gross Profit (ttm) 21 billion, EBITDA 13.29 billion, Net Income Avi to Common (ttm) 301 million and Diluted EPS (ttm) 0.24.
- As research-based biopharmaceutical company Gilead Sciences Inc discovers, develops, and commercialises medicines in the areas of unmet medical need in the United States, Europe, and internationally.
- Gilead Sciences Inc delivered a stable performance despite the economic impact which resulted from the global coronavirus pandemic. This stable performance can be largely owed to the company’s diverse portfolio, as well as its strong medical supplies sector which witnessed growing demand as hospitals geared up to combat the virus.
- With sound financials and significant, consistent, and continuous growth forecasted for the remainder of 2025, shareholders who buy or sell shares can expect lucrative dividends and returns.
- Overall, the company’s a stable performance has resulted in healthy dividends and a good share price for investors who choose to purchase shares today, securing a decent buy-in in 2025 and in the future.
Sector
Healthcare
Industry
Drug Manufacturers
Sub industry
Pharmaceuticals, Biotech
Latest News
Gilead Sciences: How to buy Gilead Sciences Shares Online
Here are the steps you need to follow to buy Gilead Sciences Inc shares with utmost confidence:
- Navigate to the AvATrade website and select ‘Register’.
- Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
- As soon as your account application has been reviewed and approved, you can select your trading platform from AvATrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
- Once you have downloaded the trading platform of your choice, you can use your AvATrade live account details to log into your AvATrade account on the trading platform.
- From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select ‘Gilead Sciences Inc’ or ‘GILD’ to buy/purchase shares.
- Alternatively, you can make use of AvATrade’s online Web Trader or the AvATradeGo mobile application.
Trading CFDs and Stocks with AvATrade provides traders with the following benefits:
- Leverage of up to 1:20.
- Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
- Indices, stocks, and commodities can all be traded form a single screen.
- Client support is presented live in a multitude of languages.
- Traders have exclusive access to a variety of educational tools.
- Trades can be executed across multiple platforms.
More shares that can be purchased through AvATrade, can be viewed here.
FAQ
Can I buy Gilead Sciences Inc shares in South Africa?
Yes, you can.
How to buy Gilead Sciences Inc shares?
By simply opening a free account with SA Shares, or by clicking the “Buy this Share” button to get started.
What is the current share price?
By clicking on the link provided above, you can view the real-time Gilead Sciences Inc share price on the platform.
Is Gilead Sciences Inc a good share to buy?
Yes, it is. Despite the growing concerns surrounding Covid-19, Gilead Sciences Inc is continuing manufacturing, sales and delivery of its products and it is forecasted to be one of the very few automotive companies to make a significant rebound post-Covid-19.
Can I buy Gilead Sciences Inc CFD through SA Shares?
Yes, you can.
Top 4 Brokers
